Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
1.
Cell Mol Biol Lett ; 29(1): 14, 2024 Jan 16.
Artículo en Inglés | MEDLINE | ID: mdl-38225555

RESUMEN

Rheumatoid arthritis (RA) is an autoimmune disease involving T and B lymphocytes. Autoantibodies contribute to joint deterioration and worsening symptoms. Adenosine deaminase (ADA), an enzyme in purine metabolism, influences adenosine levels and joint inflammation. Inhibiting ADA could impact RA progression. Intracellular ATP breakdown generates adenosine, which increases in hypoxic and inflammatory conditions. Lymphocytes with ADA play a role in RA. Inhibiting lymphocytic ADA activity has an immune-regulatory effect. Synovial fluid levels of ADA are closely associated with the disease's systemic activity, making it a useful parameter for evaluating joint inflammation. Flavonoids, such as quercetin (QUE), are natural substances that can inhibit ADA activity. QUE demonstrates immune-regulatory effects and restores T-cell homeostasis, making it a promising candidate for RA therapy. In this review, we will explore the impact of QUE in suppressing ADA and reducing produced the inflammation in RA, including preclinical investigations and clinical trials.


Asunto(s)
Inhibidores de la Adenosina Desaminasa , Artritis Reumatoide , Quercetina , Humanos , Adenosina , Adenosina Desaminasa/metabolismo , Artritis Reumatoide/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Quercetina/farmacología , Inhibidores de la Adenosina Desaminasa/farmacología
2.
Amino Acids ; 55(12): 1729-1743, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37517044

RESUMEN

Adenosine deaminase (ADA) is a Zn2+-containing enzyme that catalyzes the irreversible deamination of adenosine to inosine or deoxyadenosine to deoxyinosine. In addition to this enzymatic function, ADA mediates cell-to-cell interactions involved in lymphocyte co-stimulation or endothelial activation. ADA is implicated in cardiovascular pathologies such as atherosclerosis and certain types of cancers, including lymphoma and leukemia. To date, only two drugs (pentostatin and cladribine) have been approved for the treatment of hairy cell leukemia. In search of natural ADA inhibitors, we demonstrated the binding of selected phenolic compounds to the active site of ADA using molecular docking and molecular dynamics simulation. Our results show that phenolic compounds (chlorogenic acid, quercetin, and hyperoside) stabilized the ADA complex by forming persistent interactions with the catalytically essential Zn2+ ion. Furthermore, MM-GBSA ligand binding affinity calculations revealed that hyperoside had a comparable binding energy score (ΔG = - 46.56 ± 8.26 kcal/mol) to that of the cocrystal ligand in the ADA crystal structure (PDB ID: 1O5R) (ΔG = - 51.97 ± 4.70 kcal/mol). Similarly, chlorogenic acid exhibited a binding energy score (ΔG = - 18.76 ± 4.60 kcal/mol) comparable to those of the two approved ADA inhibitor drugs pentostatin (ΔG = - 14.54 ± 2.25 kcal/mol) and cladribine (ΔG = - 25.52 ± 4.10 kcal/mol) while quercetin was found to have modest binding affinity (ΔG = - 8.85 ± 7.32 kcal/mol). This study provides insights into the possible inhibitory potential of these phenolic compounds against ADA.


Asunto(s)
Inhibidores de la Adenosina Desaminasa , Pentostatina , Inhibidores de la Adenosina Desaminasa/farmacología , Inhibidores de la Adenosina Desaminasa/química , Simulación del Acoplamiento Molecular , Quercetina/farmacología , Cladribina , Ligandos , Ácido Clorogénico , Simulación de Dinámica Molecular
3.
Int J Mol Sci ; 24(7)2023 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-37047766

RESUMEN

Altered RNA editing has been linked to several neurodevelopmental disorders, including autism spectrum disorder (ASD) and intellectual disability, in addition to depression, schizophrenia, some cancers, viral infections and autoimmune disorders. The human ADAR2 is a potential therapeutic target for managing these various disorders due to its crucial role in adenosine to inosine editing. This study applied consensus scoring to rank potential ADAR2 inhibitors after performing molecular docking with AutoDock Vina and Glide (Maestro), using a library of 35,161 compounds obtained from traditional Chinese medicine. A total of 47 compounds were predicted to be good binders of the human ADAR2 and had insignificant toxicity concerns. Molecular dynamics (MD) simulations, including the molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) procedure, also emphasized the binding of the shortlisted compounds. The potential compounds had plausible binding free energies ranging from -81.304 to -1068.26 kJ/mol from the MM/PBSA calculations. ZINC000085511995, a naphthoquinone had more negative binding free energy (-1068.26 kJ/mol) than inositol hexakisphosphate (IHP) [-873.873 kJ/mol], an agonist and a strong binder of ADAR2. The potential displacement of IHP by ZINC000085511995 in the IHP binding site of ADAR2 could be explored for possible deactivation of ADAR2. Bayesian-based biological activity prediction corroborates the neuropharmacological, antineoplastic and antiviral activity of the potential lead compounds. All the potential lead compounds, except ZINC000014612330 and ZINC000013462928, were predicted to be inhibitors of various deaminases. The potential lead compounds also had probability of activity (Pa) > 0.442 and probability of inactivity (Pi) < 0.116 values for treating acute neurologic disorders, except for ZINC000085996580 and ZINC000013462928. Pursuing these compounds for their anti-ADAR2 activities holds a promising future, especially against neurological disorders, some cancers and viral infections caused by RNA viruses. Molecular interaction, hydrogen bond and per-residue decomposition analyses predicted Arg400, Arg401, Lys519, Trp687, Glu689, and Lys690 as hot-spot residues in the ADAR2 IHP binding site. Most of the top compounds were observed to have naphthoquinone, indole, furanocoumarin or benzofuran moieties. Serotonin and tryptophan, which are beneficial in digestive regulation, improving sleep cycle and mood, are indole derivatives. These chemical series may have the potential to treat neurological disorders, prion diseases, some cancers, specific viral infections, metabolic disorders and eating disorders through the disruption of ADAR2 pathways. A total of nine potential lead compounds were shortlisted as plausible modulators of ADAR2.


Asunto(s)
Inhibidores de la Adenosina Desaminasa , Enfermedades Transmisibles , Neoplasias , Humanos , Teorema de Bayes , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Inhibidores de la Adenosina Desaminasa/farmacología
4.
J Biomol Struct Dyn ; 41(2): 377-385, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-34851227

RESUMEN

Adenosine deaminase is a zinc+2 dependent key enzyme of purine metabolism which irreversibly converts adenosine to inosine and form ammonia. Overexpression of adenosine deaminase has been linked to a variety of pathophysiological conditions such as atherosclerosis, hypertension, and diabetes. In the case of a cell-mediated immune response, ADA is thought to be a marker, particularly in type II diabetes. Deoxycoformycin is the most potent ADA inhibitor that has been discovered so far, but it has several drawbacks, including being toxic and having poor pharmacokinetics. Taxifolin, a flavonoid derived from plants, was discovered to be a potent inhibitor of the human ADA (hADA) enzyme in the current study. Taxifolin bound at the active site of human ADA and showed fifty percent inhibition at a concentration of 400 µM against the enzyme. To better understand the interactions between taxifolin and human ADA, docking and molecular dynamic simulations were performed. In-silico studies using autodock revealed that taxifolin bound in the active site of human ADA with a binding energy of -7.4 kcal mol -1 and a theoretical Ki of 3.7 uM. Comparative analysis indicated that taxifolin and deoxycoformycin share a common binding space in the active site of human ADA and inhibit its catalytic activity similarly. The work emphasises the need of employing taxifolin as a lead chemical in order to produce a more precise and effective inhibitor of the human ADA enzyme with therapeutic potential.Communicated by Ramaswamy H. Sarma.


Asunto(s)
Adenosina Desaminasa , Diabetes Mellitus Tipo 2 , Humanos , Adenosina Desaminasa/química , Adenosina Desaminasa/metabolismo , Pentostatina/farmacología , Inhibidores de la Adenosina Desaminasa/farmacología , Inhibidores de la Adenosina Desaminasa/química
5.
Exp Parasitol ; 243: 108384, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36154837

RESUMEN

Protein-ligand (GOLD) docking of the NCI compounds into the ligand-binding site of Plasmodium falciparum adenosine deaminase (PfADA) identified three most active azo compounds containing 4-[(4-hydroxy-2-oxo-1H-quinolin-3-yl) moiety. These compounds showed IC50 of 3.7-15.4 µM against PfADA, as well as inhibited the growth of P. falciparum strains 3D7 (chloroquine (CQ)-sensitive) and K1 (CQ-resistant) with IC50 of 1.8-3.1 and 1.7-3.6 µM, respectively. The identified compounds have structures similar to the backbone structure (4-N-(7-chloroquinolin-4-yl)) in CQ, and NSC45545 could mimic CQ by inhibiting the bioformation of hemozoin in parasitic food vacuole. The amount of in situ hemozoin in the ring-stage parasite was determined using a combination of synchrotron transmission Fourier transform infrared microspectroscopy and Principal Component Analysis. Stretching of the C-O bond of hemozoin propionate group measured at 1220-1210 cm-1 in untreated intraerythrocytic P. falciparum strains 3D7 and K1 was disappeared following treatment with 1.85 and 1.74 µM NSC45545, similar to those treated with 0.02 and 0.13 µM CQ, respectively. These findings indicate a novel dual function of 4-[(4-hydroxy-2-oxo-1H-quinolin-3-yl) azo compounds in inhibiting both PfADA and in situ hemozoin biocrystallization. These lead compounds hold promise for further development of new antimalarial therapeutics that could delay the onset of parasitic drug resistance.


Asunto(s)
Inhibidores de la Adenosina Desaminasa , Antimaláricos , Compuestos Azo , Plasmodium falciparum , Adenosina Desaminasa , Antimaláricos/farmacología , Compuestos Azo/farmacología , Biomineralización , Cloroquina/farmacología , Resistencia a Medicamentos , Ligandos , Plasmodium falciparum/efectos de los fármacos , Inhibidores de la Adenosina Desaminasa/farmacología
6.
Gene ; 813: 146124, 2022 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-34921950

RESUMEN

The knowledge of RNA editing modifications and its subsequent proteomic diversity in is still limited and represents only the tip of the iceberg. Adenosine to inosine (A-to-I) RNA editing is the most prevalent in RNA editome with a rising role for ADARgene family as a major regulator of the dynamic landscape of RNA editing. This study aimed at evaluating the potential chemopreventive effects of the epigenetic regulator "pterostilbene" in diethylnitrosamine (DEN)-exposedrat model. Consequently, the hepatic Adars expression was investigated as a possible mechanism for mediation of the putative pterostilbene-induced chemopreventive effect. The effects of administration of pterostilbene were investigated on the structural changes, immunohistochemical staining, liver function test, serum alpha feto-protein (AFP), IL-6, and hepatic Adar1 and Adar2 relative gene expression at the beginning and at the 6th week of the study. Pterostilbene attenuated DEN-induced liver injury, improves hepatocyte parrafin-1 (Hep Par-1), decreases heat shock protein 70 (HSP70), improved AFP, serum albumin, transaminases, IL-6 with alleviation of disturbed hepatic Adar1 and Adar2 expression. This study spotlights the role of pterostilbene in attenuation of DEN-induced liver injury which could be mediated, at least partially, through the alleviation of the aberrant expression of Adar enzymes. Yet, more in-depth studies are needed to further elucidate the molecular mechanisms underlying the effects of pterostilbene on RNA editing enzymes.


Asunto(s)
Adenosina Desaminasa/biosíntesis , Cirrosis Hepática/tratamiento farmacológico , Estilbenos/farmacología , Adenosina Desaminasa/genética , Inhibidores de la Adenosina Desaminasa/farmacología , Animales , Dietilnitrosamina/administración & dosificación , Expresión Génica , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática/enzimología , Cirrosis Hepática/genética , Cirrosis Hepática/patología , Masculino , Proteómica , Edición de ARN , Proteínas de Unión al ARN/genética , Ratas , Ratas Wistar , Transcriptoma
7.
J Biomol Struct Dyn ; 40(11): 5112-5127, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-33397209

RESUMEN

Novel coronavirus (COVID-19) responsible for viral pneumonia which emerged in late 2019 has badly affected the world. No clinically proven drugs are available yet as the targeted therapeutic agents for the treatment of this disease. The viral main protease which helps in replication and transcription inside the host can be an effective drug target. In the present study, we aimed to discover the potential of ß-adrenoceptor agonists and adenosine deaminase inhibitors which are used in asthma and cancer/inflammatory disorders, respectively, as repurposing drugs against protease inhibitor by ligand-based and structure-based virtual screening using COVID-19 protease-N3 complex. The AARRR pharmacophore model was used to screen a set of 22,621 molecules to obtain hits, which were subjected to high-throughput virtual screening. Extra precision docking identified four top-scored molecules such as +/--fenoterol, FR236913 and FR230513 with lower binding energy from both categories. Docking identified three major hydrogen bonds with Gly143, Glu166 and Gln189 residues. 100 ns MD simulation was performed for four top-scored molecules to analyze the stability, molecular mechanism and energy requirements. MM/PBSA energy calculation suggested that van der Waals and electrostatic energy components are the main reasons for the stability of complexes. Water-mediated hydrogen bonds between protein-ligand and flexibility of the ligand are found to be responsible for providing extra stability to the complexes. The insights gained from this combinatorial approach can be used to design more potent and bio-available protease inhibitors against novel coronavirus.Communicated by Ramaswamy H. Sarma.


Asunto(s)
Inhibidores de la Adenosina Desaminasa , Agonistas Adrenérgicos , Antivirales , Proteasas 3C de Coronavirus , SARS-CoV-2 , Inhibidores de la Adenosina Desaminasa/química , Inhibidores de la Adenosina Desaminasa/farmacología , Agonistas Adrenérgicos/química , Agonistas Adrenérgicos/farmacología , Antivirales/química , Antivirales/farmacología , Proteasas 3C de Coronavirus/antagonistas & inhibidores , Reposicionamiento de Medicamentos , Humanos , Ligandos , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Receptores Adrenérgicos , SARS-CoV-2/efectos de los fármacos , Tratamiento Farmacológico de COVID-19
8.
Bioorg Med Chem ; 43: 116272, 2021 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-34157570

RESUMEN

Inhibitors of the enzyme adenosine monophosphate deaminase (AMPD) show interesting levels of herbicidal activity. An enzyme mechanism-based approach has been used to design new inhibitors of AMPD starting from nebularine (6) and resulting in the synthesis of 2-deoxy isonebularine (16). This compound is a potent inhibitor of the related enzyme adenosine deaminase (ADA; IC50 16 nM), binding over 5000 times more strongly than nebularine. It is proposed that the herbicidal activity of compound 16 is due to 5́-phosphorylation in planta to give an inhibitor of AMPD. Subsequently, an enzyme structure-based approach was used to design new non-ribosyl AMPD inhibitors. The initial lead structure was discovered by in silico screening of a virtual library against plant AMPD. In a second step, binding to AMPD was further optimised via more detailed molecular modeling leading to 2-(benzyloxy)-5-(imidazo[2,1-f][1,2,4]triazin-7-yl)benzoic acid (36) (IC50 300 nM). This compound does not inhibit ADA and shows excellent selectivity for plant over human AMPD.


Asunto(s)
AMP Desaminasa/antagonistas & inhibidores , Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Diseño de Fármacos , AMP Desaminasa/metabolismo , Inhibidores de la Adenosina Desaminasa/síntesis química , Inhibidores de la Adenosina Desaminasa/química , Relación Dosis-Respuesta a Droga , Humanos , Estructura Molecular , Relación Estructura-Actividad
9.
Mar Drugs ; 18(12)2020 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-33271765

RESUMEN

This study was designed to investigate the effects and underlying mechanisms of Astaxanthin (AST) on high-fructose-induced hyperuricemia (HUA) from the perspectives of the uric acid (UA) synthesis and excretion in rat models. Following six weeks of a 10% fructose diet, the level of serum UA effectively decreased in the AST groups as compared to the model group. The enzymatic activities of xanthine oxidase (XOD) and adenosine deaminase (ADA) were significantly inhibited, and the mRNA expression levels of XOD and ADA significantly decreased after the AST administration. These results suggested that the AST reduced UA synthesis by inhibiting the mRNA expressions and enzyme activities of XOD and ADA, thereby contributing to HUA improvement. On the hand, the relative expressions of the mRNA and protein of kidney reabsorption transport proteins (GLUT9 and URAT1) were significantly down-regulated by AST, while that of the kidney secretion proteins (OAT1, OAT3 and ABCG2) were significantly up-regulated by AST. These results indicated that the AST promoted UA excretion by regulating the urate transport proteins, and thus alleviated HUA. This study suggested that the AST could serve as an effective alternative to traditional medicinal drugs for the prevention of fructose-induced HUA.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Hiperuricemia/prevención & control , Proteínas de Transporte de Membrana/efectos de los fármacos , Ácido Úrico/sangre , Xantina Oxidasa/antagonistas & inhibidores , Adenosina Desaminasa/genética , Animales , Biomarcadores/sangre , Biomarcadores/orina , Modelos Animales de Enfermedad , Fructosa , Hiperuricemia/inducido químicamente , Hiperuricemia/enzimología , Riñón/efectos de los fármacos , Riñón/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Proteínas de Transporte de Membrana/genética , Proteínas de Transporte de Membrana/metabolismo , Ratas Sprague-Dawley , Reabsorción Renal/efectos de los fármacos , Ácido Úrico/orina , Xantina Oxidasa/genética , Xantina Oxidasa/metabolismo , Xantófilas/farmacología
10.
Sci Rep ; 10(1): 17809, 2020 10 20.
Artículo en Inglés | MEDLINE | ID: mdl-33082435

RESUMEN

The behavioural impacts of prenatal exposure to ethanol include a lower IQ, learning problems, anxiety and conduct disorders. Several components of the neurochemical network could contribute to the long-lasting effects of ethanol embryonic exposure. Adenosine is an important neuromodulator, that has been indicated to be affected by acute and chronic exposure to ethanol. Here, embryos of zebrafish exposed to 1% ethanol during the developmental stages of gastrula/segmentation or pharyngula exhibited anxiolytic effect, increased aggressiveness, and decreased social interaction. The exposure during pharyngula stage was able to affect all behavioural parameters analysed at 3 months-post fertilization (mpf), while the treatment during gastrula stage affected the anxiety and social interaction parameters. The aggressiveness was the only behavioural effect of early ethanol exposure that lasted to 12 mpf. The use of a specific inhibitor of adenosine production, the inhibitor of ecto-5'-nucleotidase (AMPCP/150 mg/kg), and the specific inhibitor of adenosine degradation, the inhibitor of adenosine deaminase, EHNA (100 mg/kg) did not affect the effects over anxiety. However, AMPCP at 3 mpf, but not EHNA, reversed aggressive parameters. AMPCP also recovered the social interaction parameter at 3 mpf in animals treated in both stages, while EHNA recovered this parameter just in those animals treated with ethanol during the gastrula stage. These results suggest that long-lasting behavioural effects of ethanol can be modulated by intervention on ecto-5'-nucleotidase and adenosine deaminase activities.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/uso terapéutico , Adenosina Difosfato/análogos & derivados , Adenosina/metabolismo , Trastorno de Personalidad Antisocial/tratamiento farmacológico , Etanol/efectos adversos , Efectos Tardíos de la Exposición Prenatal/tratamiento farmacológico , 5'-Nucleotidasa/antagonistas & inhibidores , Adenina/análogos & derivados , Adenina/farmacología , Adenina/uso terapéutico , Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Difosfato/farmacología , Adenosina Difosfato/uso terapéutico , Animales , Trastorno de Personalidad Antisocial/etiología , Conducta Animal , Modelos Animales de Enfermedad , Etanol/administración & dosificación , Femenino , Humanos , Embarazo , Interacción Social/efectos de los fármacos , Pez Cebra
11.
ChemMedChem ; 15(22): 2151-2156, 2020 11 18.
Artículo en Inglés | MEDLINE | ID: mdl-32729197

RESUMEN

Adenosine deaminase (ADA) is a human mononuclear Zn2+ metalloenzyme that converts adenosine to inosine. ADA is a validated drug target for cancer, but there has been little recent work on the development of new therapeutics against this enzyme. The lack of new advancements can be partially attributed to an absence of suitable assays for high-throughput screening (HTS) against ADA. To facilitate more rapid drug discovery efforts for this target, an in vitro assay was developed that utilizes the enzymatic conversion of a visibly emitting adenosine analogue to the corresponding fluorescent inosine analogue by ADA, which can be monitored via fluorescence intensity changes. Utilizing this assay, a library of ∼350 small molecules containing metal-binding pharmacophores (MBPs) was screened in an HTS format to identify new inhibitor scaffolds against ADA. This approach yielded a new metal-binding scaffold with a Ki value of 26±1 µM.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Oxazoles/farmacología , Zinc/farmacología , Inhibidores de la Adenosina Desaminasa/síntesis química , Inhibidores de la Adenosina Desaminasa/química , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Humanos , Estructura Molecular , Oxazoles/química , Zinc/química
12.
J Recept Signal Transduct Res ; 40(1): 77-88, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31971048

RESUMEN

Adenosine deaminase (ADA) is an enzyme present in purine metabolic pathway. Its inhibitors are considered to be potent drug lead compounds against inflammatory and malignant diseases. This study aimed to test ADA inhibitory activity of some Streptomyces secondary metabolites by using computational and in vitro methods. The in silico screening of the inhibitory properties has been carried out using pharmacophore modeling, docking, and molecular dynamics studies. The in vitro validation of the selected antibiotics has been carried out by enzyme kinetics and fluorescent spectroscopic studies. The results indicated that novobiocin, an aminocoumarin antibiotic from Streptomyces niveus, has significant inhibition on ADA activity. Hence, the antibiotic can be used as a lead compound for the development of potential ADA inhibitors.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Antibacterianos/farmacología , Reposicionamiento de Medicamentos , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Streptomyces/química , Inhibidores de la Adenosina Desaminasa/química , Aminoglicósidos/química , Aminoglicósidos/farmacología , Dominio Catalítico , Evaluación Preclínica de Medicamentos , Pruebas de Enzimas , Humanos , Análisis de los Mínimos Cuadrados , Ligandos , Novobiocina/química , Novobiocina/farmacología , Relación Estructura-Actividad Cuantitativa , Espectrometría de Fluorescencia
13.
Folia Microbiol (Praha) ; 65(2): 293-302, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31273645

RESUMEN

Medicinal plants have been studied for potential endophytic interactions and numerous studies have provided evidence that seeds harbor diverse microbial communities, not only on their surfaces but also within the embryo. Adenosine deaminase (ADA) is known as a potential therapeutic target for the treatment of lymphoproliferative disorders and cancer. Therefore, in this study, 20 types of medicinal plant seeds were used to screen endophytic fungi with tissue homogenate and streak. In addition, 128 morphologically distinct endophyte strains were isolated and their ADA inhibitory activity determined by a spectrophotometric assay. The strain with the highest inhibitory activity was identified as Cochliobolus sp. Seven compounds were isolated from the strain using a chromatography method. Compound 3 showed the highest ADA inhibitory activity and was identified as 5-hydroxy-2-hydroxymethyl-4H-pyran-4-one, based on the results of 1H and 13C NMR spectroscopy. The results of molecular docking suggested that compound 3 binds to the active site and the nonspecific binding site of the ADA. Furthermore, we found that compound 3 is a mixed ADA inhibitor. These results indicate that endophytic strains are a promising source of ADA inhibitors and that compound 3 may be a superior source for use in the preparation of biologically active ADA inhibitor compounds used to treat cancer.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/química , Ascomicetos/química , Endófitos/química , Plantas Medicinales/microbiología , Adenosina Desaminasa/química , Adenosina Desaminasa/metabolismo , Inhibidores de la Adenosina Desaminasa/farmacología , Ascomicetos/clasificación , Ascomicetos/genética , Ascomicetos/aislamiento & purificación , Sitios de Unión , Endófitos/clasificación , Endófitos/genética , Endófitos/aislamiento & purificación , Humanos , Espectroscopía de Resonancia Magnética , Simulación del Acoplamiento Molecular , Neoplasias/tratamiento farmacológico , Neoplasias/enzimología , Semillas/microbiología
14.
Int J Biol Macromol ; 141: 1246-1257, 2019 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-31520704

RESUMEN

Adenosine deaminase is a critical enzyme in purine metabolism that regulates intra and extracellular adenosine concentrations by converting it to inosine. Adenosine is an important purine that regulates numerous physiological functions by interacting with its receptors. Adenosine and consequently adenosine deaminase can have pro or anti-inflammatory effects on tissues depending on how much time has passed from the start of the injury. In addition, an increase in adenosine deaminase activity has been reported for various diseases and the significant effect of deaminase inhibition on the clinical course of different diseases has been reported. However, the use of inhibitors is limited to only a few medical indications. Data on the increase of adenosine deaminase activity in different diseases and the impact of its inhibition in various cases have been collected and are discussed in this review. Overall, the evidence shows that many studies have been done to introduce inhibitors, however, in vivo studies have been much less than in vitro, and often have not been expanded for clinical use.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Adenosina/metabolismo , Inhibidores de la Adenosina Desaminasa/uso terapéutico , Animales , Humanos , Transducción de Señal/efectos de los fármacos
15.
Comput Biol Chem ; 83: 107111, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31445420

RESUMEN

Epigallocatechin gallate, a flavonoid from Camellia sinensis possess various pharmacological activities such as anticancer, antimicrobial and antioxidant etc. Adenosine deaminase, (ADA), is a key enzyme involved in the purine metabolism, the inhibitors of which is being considered as highly promising candidate for the development of anti-proliferative and anti-inflammatory drugs. In this work we studied adenosine deaminase inhibitory activity of epigallocatechin gallate by using biophysical and computational methods. The enzyme inhibition study result indicated that epigallocatechin gallate possess strong inhibitory activity on ADA. ITC study revealed the energetics of binding. Also the binding is confirmed by using fluorescence spectroscopy. The structural details of binding are obtained from molecular docking and MD simulation studies.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Catequina/análogos & derivados , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Inhibidores de la Adenosina Desaminasa/química , Calorimetría , Camellia sinensis/química , Catequina/química , Catequina/farmacología , Humanos , Espectrometría de Fluorescencia , Termodinámica
16.
J Neurochem ; 150(3): 282-295, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31121068

RESUMEN

Neuroinflammation is one of the driving forces of progressive neurodegeneration in Parkinson's disease (PD). The metabolomics approach has been proved highly useful in identifying potential therapeutic targets. Here, to identify inflammation-relevant treatment targets for PD, mass spectrometry-based untargeted metabolomics was applied to characterize metabolic changes in the striatum of mice with double-hit PD induced by lipopolysaccharide plus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Seven days after the final MPTP administration, metabolites from the purine metabolism pathway, including adenosine, 1-methyladenosine, adenine, inosine, hypoxanthine, xanthine, xanthosine, and guanosine, were found to be significantly dysregulated. The metabolite-protein interaction network and changes in the concentration ratio of these metabolites indicated that adenosine and adenosine deaminase (ADA; EC 3.5.4.4) were the most promising therapeutic targets and adenosine augmentation might be a rational approach to slow PD progression. These findings were then verified in a subacute MPTP-induced PD mouse model treated with ADA inhibition alone or in conjunction with antagonism of adenosine A2A receptors (A2A R). Behavioral, biochemical, and immunohistochemical analysis demonstrated that ADA inhibition significantly ameliorated the MPTP-mediated motor disabilities, dopamine depletion, and dopaminergic cell death. Significantly enhanced neuroprotective effects were further observed when the ADA inhibitor was utilized in conjunction with an A2A R antagonist. Together, our study indicated for the first time that ADA inhibitors protected against neurodegeneration induced by the neurotoxin MPTP, and ADA inhibitors in combination with A2A R antagonists showed additive antiparkinsonian effects.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/metabolismo , Antiparkinsonianos/farmacología , Trastornos Parkinsonianos/metabolismo , Animales , Modelos Animales de Enfermedad , Masculino , Metabolómica , Ratones , Ratones Endogámicos C57BL , Antagonistas de Receptores Purinérgicos P1/farmacología
17.
Comb Chem High Throughput Screen ; 22(2): 113-122, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30987561

RESUMEN

BACKGROUND: Adenosine deaminase (ADA) is an important enzyme in purine metabolism and is known as a potential therapeutic target for the treatment of lymphoproliferative disorders and cancer. Traditional Chinese Herbal Medicine (TCHM) is widely used alone or in combination with chemotherapy to treat cancer, due to its ability to deliver a broad variety of bioactive secondary metabolites as promising sources of novel organic natural agents. OBJECTIVE: In the present study, 29 varieties of medicinal plants were screened for the presence of ADA inhibitors. RESULTS: Extracts from Reynoutria japonica, Glycyrrhiza uralensis, Lithospermum erythrorhizon, Magnolia officinalis, Gardenia jasminoides, Stephania tetrandra, Commiphora myrrha, Raphanus sativus and Corydalis yanhusuo demonstrated strong ADA inhibition with rates greater than 50%. However, Reynoutria japonica possessed the highest ADA inhibitory activity at 95.26% and so was used in our study for isolating the ADA inhibitor to be further studied. Eight compounds were obtained and their structures were identified. The compound H1 had strong ADA inhibitory activity and was deduced to be emodin by 1H and 13C-NMR spectroscopic analysis with an IC50 of 0.629 mM. The molecular docking data showed that emodin could bind tightly to the active site of ADA. Our results demonstrated that emodin displayed a new biological activity which is ADA inhibitory activity with high cytotoxic activity against K562 leukemia cells. The bioactivity of cordycepin was significantly increased when used in combination with emodin. CONCLUSION: Emodin may represent a good candidate anti-cancer therapy and adenosine protective agent.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Antineoplásicos/farmacología , Emodina/farmacología , Medicina Tradicional China , Extractos Vegetales/química , Polygonaceae/química , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Células K562
18.
Arch Biochem Biophys ; 667: 6-13, 2019 05 30.
Artículo en Inglés | MEDLINE | ID: mdl-31002765

RESUMEN

Plasmodium falciparum (Pf), a malarial pathogen, can only synthesize purine nucleotides employing a salvage pathway because it lacks de novo biosynthesis. Adenosine deaminase (ADA), one of the three purine salvage enzymes, catalyzes the irreversible hydrolytic deamination of adenosine to inosine, which is further converted to GMP and AMP for DNA/RNA production. In addition to adenosine conversion, Plasmodium ADA also catalyzes the conversion of 5'-methylthioadenosine, derived from polyamine biosynthesis, into 5'-methylthioinosine whereas the human enzyme is not capable of this function. Here we report the crystal structure of a surface engineered PfADA at a resolution of 2.48 Å, together with results on kinetic studies of PfADA wild-type and active site variants. The structure reveals a novel inosine binding pocket linked to a distinctive PfADA substructure (residues 172-179) derived from a non-conserved gating helix loop (172-188) in Plasmodium spp. and other ADA enzymes. Variants of PfADA and human (h) ADA active site amino acids were generated in order to study their role in catalysis, including PfADA- Phe136, -Thr174, -Asp176, and -Leu179, and hADA-Met155, equivalent to PfADA-Asp176. PfADA-Leu179His showed no effect on kinetic parameters. However, kinetic results of PfADA-Asp176Met/Ala mutants and hADA-Met155Asp/Ala showed that the mutation reduced adenosine and 5'-methylthioadenosine substrate affinity in PfADA and kcat in hADA, thereby reducing catalytic efficiency of the enzyme. Phe136Leu mutant showed increased Km (>10-fold) for both substrates whereas Thr174Ile/Ala only affected 5'-methylthioadenosine binding affinity. Together, the structure with the novel inosine binding pocket and the kinetic data provide insights for rational design of inhibitors against PfADA.


Asunto(s)
Adenosina Desaminasa/química , Plasmodium falciparum/enzimología , Proteínas Protozoarias/química , Adenosina Desaminasa/genética , Adenosina Desaminasa/metabolismo , Inhibidores de la Adenosina Desaminasa/química , Inhibidores de la Adenosina Desaminasa/farmacología , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Dominio Catalítico , Cristalografía por Rayos X , Diseño de Fármacos , Humanos , Inosina/metabolismo , Cinética , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Plasmodium falciparum/genética , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Homología de Secuencia de Aminoácido , Especificidad por Sustrato
19.
PLoS One ; 13(11): e0207234, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30444912

RESUMEN

Adenosine deaminase (ADA) catalyzes the deamination of adenosine, which is important in purine metabolism. ADA is ubiquitous to almost all human tissues, and ADA abnormalities have been reported in various diseases, including rheumatoid arthritis. ADA can be divided into two conformations based on the inhibitor that it binds to: open and closed forms. Here, we chose three ligands, namely, FR117016 (FR0), FR221647 (FR2) (open form), and HDPR (PRH, closed form), to investigate the inhibition mechanism of ADA and its effect on ADA through molecular dynamics simulations. In open forms, Egap and electrostatic potential (ESP) indicated that electron transfer might occur more easily in FR0 than in FR2. Binding free energy and hydrogen bond occupation revealed that the ADA-FR0 complex had a more stable structure than ADA-FR2. The probability of residues Pro159 to Lys171 of ADA-FR0 and ADA-FR2 to form a helix moderately increased compared with that in nonligated ADA. In comparison with FR0 and FR2 PRH could maintain ADA in a closed form to inhibit the function of ADA. The α7 helix (residues Thr57 to Ala73) of ADA in the closed form was mostly unfastened because of the effect of PRH. The number of H bonds and the relative superiority of the binding free energy indicated that the binding strength of PRH to ADA was significantly lower than that of an open inhibitor, thereby supporting the comparison of the inhibitory activities of the three ligands. Alanine scanning results showed that His17, Gly184, Asp295, and Asp296 exerted the greatest effects on protein energy, suggesting that they played crucial roles in binding to inhibitors. This study served as a theoretical basis for the development of new ADA inhibitors.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Adenosina Desaminasa/química , Adenosina Desaminasa/genética , Adenosina Desaminasa/metabolismo , Inhibidores de la Adenosina Desaminasa/química , Sitios de Unión/genética , Estabilidad de Enzimas , Humanos , Enlace de Hidrógeno , Cinética , Ligandos , Simulación de Dinámica Molecular , Mutagénesis Sitio-Dirigida , Análisis de Componente Principal , Conformación Proteica , Conformación Proteica en Hélice alfa , Teoría Cuántica , Electricidad Estática
20.
J Cell Mol Med ; 22(12): 5939-5954, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30291675

RESUMEN

The activity of a cell-surface ecto-adenosine deaminase (eADA) is markedly increased in the endothelial activation and vascular inflammation leading to decreased adenosine concentration and alterations in adenosine signalling. Depending on the specific pathway activated, extracellular purines mediate host cell response or regulate growth and cytotoxicity on tumour cells. The aim of this study was to test the effects of adenosine deaminase inhibition by 2'deoxycoformycin (dCF) on the breast cancer development. dCF treatment decreased a tumour growth and a final tumour mass in female BALB/c mice injected orthotopically with 4T1 cancer cells. dCF also counteracted cancer-induced endothelial dysfunction in orthotopic and intravenous 4T1 mouse breast cancer models. In turn, this low dCF dose had a minor effect on immune stimulation exerted by 4T1 cell implantation. In vitro studies revealed that dCF suppressed migration and invasion of 4T1 cells via A2a and A3 adenosine receptor activation as well as 4T1 cell adhesion and transmigration through the endothelial cell layer via A2a receptor stimulation. Similar effects of dCF were observed in human breast cancer cells. Moreover, dCF improved a barrier function of endothelial cells decreasing its permeability. This study highlights beneficial effects of adenosine deaminase inhibition on breast cancer development. The inhibition of adenosine deaminase activity by dCF reduced tumour size that was closely related to the decreased aggressiveness of tumour cells by adenosine receptor-dependent mechanisms and endothelial protection.


Asunto(s)
Inhibidores de la Adenosina Desaminasa/farmacología , Progresión de la Enfermedad , Neoplasias Mamarias Animales/metabolismo , Neoplasias Mamarias Animales/patología , Receptores Purinérgicos P1/metabolismo , Adenosina Desaminasa/metabolismo , Animales , Adhesión Celular/efectos de los fármacos , Línea Celular Tumoral , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Modelos Animales de Enfermedad , Células Endoteliales/efectos de los fármacos , Células Endoteliales/patología , Espacio Extracelular/metabolismo , Femenino , Humanos , Neoplasias Mamarias Animales/sangre , Neoplasias Mamarias Animales/irrigación sanguínea , Ratones Endogámicos BALB C , Invasividad Neoplásica , Nucleótidos/sangre , Pentostatina/farmacología , Fenotipo , Migración Transendotelial y Transepitelial/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA